Home › Free Stock Grades › PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Stock Grade
PHAT · Healthcare
A+
Market Cap
$1.2B
P/E Ratio
—
Revenue Growth (YoY)
+216.9%
Net Margin
-126.4%
Return on Equity
50.5%
Dividend Yield
None
About Phathom Pharmaceuticals, Inc.'s fundamentals
Phathom Pharmaceuticals is a $1.2 billion biotechnology company experiencing exceptional revenue growth of 216.9% year-over-year, indicating strong commercial traction in its market. However, the company is currently unprofitable with a net margin of -126.4% and reported a net loss in its latest annual statement, reflecting the typical cash-burn phase of early-stage pharmaceutical companies. The company does not pay a dividend and has no traditional P/E ratio due to its negative earnings.